🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07466108
Recruiting Not applicable

Hemodynamic Effects of Intravenous Paracetamol in Patients Undergoing Emergency Laparotomy

NCT07466108 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-03-18
Last updated
2026-03-20

Condition(s) studied

ParacetamolHypotension Drug-InducedEmergency Surgery

Investigational drug(s) / intervention(s)

Paracetamol (acetaminophen) →Placebo Control

Paracetamol (acetaminophen): Patients will receive 1 g intravenous paracetamol (prepared by withdrawing 100 mL of paracetamol into two 50 mL syringes). The drug will be infused at a rate of 600 mL/h to be completed over a period of 10 minutes

Placebo Control: Patients will receive 100 mL saline 0.9% (prepared by withdrawing 100 mL of saline 0.9% into two 50 mL syringes). The dose will be infused at a rate of 600 mL/h.

Study summary

Emergency laparotomy is a high-risk procedure often performed in patients with severe physiological derangements due to sepsis, making perioperative management challenging. Although multimodal analgesia is essential, options are often limited by factors such as hemodynamic instability, renal dysfunction, and coagulopathy. Intravenous paracetamol is commonly recommended for perioperative analgesia because of its opioid-sparing effect, but evidence suggests it may cause hypotension through peripheral vasodilation, particularly in critically ill patients. Most data on this effect come from observational studies, and evidence regarding its intraoperative hemodynamic impact remains limited.

Eligibility

Sex
ALL
Min age
21 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients, ASA I-III undergoing emergency laparotomy Exclusion Criteria: * Severe cardiac morbidities (impaired contractility with ejection fraction \< 40%, heart block, arrhythmias, tight valvular lesions) * Hemodynamically unstable patients (defined as patients with MAP \< 65 mmHg or need vasopressor to maintain MAP\>65 mmHg). * Patients with high shock index (heart rate / systolic blood pressure \>1) * Pregnant or lactating women, * Allergy of any of the study drugs

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Cairo Cairo Governorate Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07466108 on ClinicalTrials.gov ↗ ← All trials in Egypt